ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS

April 11, 2023

https://www.globenewswire.com/news-release/2023/04/11/2644926/25687/en/ClearPoint-Neuro-Extends-Software-License-and-Research-Agreement-with-Philips-to-Include-Fully-Automatic-Subnuclei-Segmentation-for-DBS.html

SOLANA BEACH, Calif., April 11, 2023 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced further expansion of its worldwide license and research agreement with Philips, a global leader in health technology, to add subnuclei segmentation applied to MRI, and potentially CT scans, for use in the operating room. The design goal of the ClearPoint Maestro® Brain Model is to enable highly accurate ClearPoint interventions under both MRI and CT guidance by facilitating patient-specific, multi-modal fusion for accurate target identification and trajectory planning.

Read more at globenewswire.com

Related news for (CLPT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.